Business
Avacta secures second Optim sale in US
Avacta secures second Optim sale in US.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 4829H Avacta Group PLC 31 May 2011 \n \n\n \n \n\n\n\n\nPress release \n\n\n31 May 2011\n\n\n\n\n \nAvacta Group plc\n(\"Avacta\" or \"the Group\")\n \nAvacta secures second Optim sale in US\nto global pharmaceutical company\nPall Life Sciences makes first sale following recent appointment as distributor\n \nAvacta Group plc (AIM:AVCT), a leading provider of analytical and diagnostic technologies and services to the pharmaceutical and animal healthcare sectors, is pleased to announce that its newly appointed sales and marketing partner for Optim in North America, Pall Corporation (NYSE:PLL) (\"Pall\"), has secured its first Optim sale, to one of the ten largest pharmaceutical companies in the US.\n \nOptim reduces the time and cost of drug development through the early analysis of compounds to identify those candidates most suitable for development and to define the optimal processing conditions. In the critical stages of pre-formulation, stability testing and formulation of biopharmaceutical drugs, Optim delivers vital information tens of times faster than other approaches using sample sizes less than a hundredth needed by existing techniques. Such efficiencies and cost reductions should allow drug developers to routinely gain important insights into candidate drug compounds at a much earlier stage of development. This in turn leads to a significant reduction in the likelihood of failure of drug compounds and reduces the overall costs of bringing new drugs to market.Optim comprises a benchtop instrument and a single-use sample holder providing recurring consumables revenues. \n \nPall Life Sciences, which provides cutting-edge products and services to the biopharma and biotech industries, was appointed as distributor for North America in February 2011. Pall has since been working with Avacta to generate new sales leads for Optim and has also been progressing the US sales pipeline that Avacta had grown before the distribution agreement was signed. In the short period since Pall's appointment, the Optim sales pipeline in the US has doubled following successful marketing events. Avacta has completed the first phase of training for Pall's sales and support teams and Pall has now closed its first sale to one of the largest global pharmaceutical companies. \n \nAla...